John Mendelsohn

Dr. Mendenlsohn is an internationally recognized leader in cancer research, and served as the president of The University of Texas MD Anderson Cancer Center from 1996 to 2011. He is currently a professor in the Department of Genomic Medicine, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, TX. Dr. Mendelsohn is an international expert on how the binding of growth factors to cell-surface receptors regulates cell functions. He was part of the team that produced monoclonal antibody 225, which inhibits human cancer cell proliferation by blocking the signaling pathways that are activated by epidermal growth factor receptors. His subsequent research in the laboratory and clinic pioneered the universally adopted concept of anti-receptor therapy that targets key cell signaling pathways as a new form of cancer treatment. Dr. Mendelsohn served 10 years as the founding editor of Clinical Cancer Research, and he has been on numerous editorial boards. He has authored more than 250 scientific papers and articles for journals and books, and is senior editor of the textbook “The Molecular Basis of Cancer.”